BioAlliance Pharma: Quarterly information as of September 30, 2012
11/14/2012 10:25:01 AM
PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, today publishes the major key milestones achieved during the third quarter of 2012. Two key achievements will reinforce the Company’s capacity to create value: The effective start of the Phase III trial with Livatag® in primary liver cancer: at the end of October, recruitment was in line with the planned schedule and ten patients have already been treated. The study, opened in twenty sites in France, should be extended to other European countries in the next weeks.
comments powered by